

ASX ANNOUNCEMENT

07 February 2022

Second Strategic Remote Patient Monitoring (RPM) Distribution/Marketing Agreement with Access Telehealth.

Highlights:

- Second, 5 Year Non-Exclusive Distribution and Marketing Agreement signed with Access Telehealth (Access) in the key US market.
- Access is a premier provider of RPM and telehealth services utilising their unique Remot/i platform that simplifies remote care delivery with patient engagement and productivity driven dashboard tools to support effective patient care and compliance.
- The Access patient engagement business model is the strategic platform allowing RespiRI to launch the high value wheezo® Remote Asthma Monitoring Program (RAMP) developed in Australia to physicians in the USA.
- Allows Access customers to claim numerous additional reimbursement CPT codes making the combined wheezo®/Access proposition financially attractive to physicians.
- Physicians claiming relevant RPM CPT reimbursement for wheezo® through Access and RespiRI will share these monthly recurring revenues. These annuity streams are in addition to the revenues generated by the sales of wheezo® devices to Access
- RespiRI continues to ramp up efforts and activities in the next critical phase of the US commercialisation pathway which is actively engaging with our RPM partners' customers and very good progress has been made in a relatively short period.
- Further third-party agreements anticipated as RespiRI builds out US RPM strategy for wheezo®.

RespiRI Limited (ASX:RSH) ("RespiRI" or the "Company"), an eHealth SaaS Company supporting respiratory health management is excited to announce its second non-exclusive distribution/marketing partnership with Remote Patient Monitoring (RPM), chronic care and telehealth provider Access www.accessrpm.com. Either party can terminate for convenience in 180 days' notice in 60 days if there has been a material breach of the Agreement. There are no associated upfront payments under the signed Agreement, with small minimum order quantities. At this early stage, RespiRI is unable to reliably quantify the future revenue potential through this Agreement by way of device sales and subscription revenues; however, the Agreement does increase potential accessibility to additional patients in the key US market. In addition to the device sales to Access, RespiRI and Access will share the Product as a Service (PaaS) monthly fees generated by the wheezo® RPM solution that will be charged to physicians and other Healthcare Professionals claiming RPM and other CPT reimbursement codes which are managed by the Access Remot/i platform.

CEO and Managing Director of RespiRI, Mr Marjan Mikel said "I am very pleased to announce our partnership with Access. What really excited RespiRI is their patient engagement business model driven by their highly trained staff together with their unique RPM platform, Remot/i. This is a perfect model that allows this partnership to launch our RAMP program into the US market quickly, well ahead of schedule and a model that has already been well received by Access clients. We are currently assessing other potential customers organised through Access. Again, this second agreement demonstrates that we continue to execute our US strategy and leveraging the highly successful physician led RAMP."

CEO of Access, Mrs Myra Armeigh said “In our experience, seeing a patient a few times a year or providing a patient with a device doesn’t always equal patient compliance. Our compassionate clinical staff work diligently to ensure patient compliance and communicate with providers and organizations to evaluate and manage patients on a regular basis. Being a distribution partner for wheezo is an important part of Access Telehealth’s long-term strategy to deliver the right tools for various chronic conditions. We believe 2022 will be an exciting and successful year for the Access Telehealth/ Respiro partnership and we look forward to helping patients breathe better.”

Access delivers an innovative digital health solution and clinical remote patient monitoring support to drive improved patient outcomes, access to care and world-class tools for chronic disease management. By integrating cutting edge digital devices like wheezo® within their remote care software solution, Access is able to provide healthcare professionals with meaningful, decision-based data needed to manage their most vulnerable patients. The Access Remoti platform uniquely simplifies remote care delivery and together with clinical patient engagement and productivity driven dashboard tools better supports effective patient care and compliance. Automated care time tracking and reimbursement reports makes it easy to boost physician reimbursement CPT code revenue to support vital chronic disease management programs including Remote Physiologic Monitoring (RPM), Remote Therapeutic Monitoring, Transitional Care, Chronic Care Management, Telemedicine and more.

Healthcare staffing issues and the impact of the Pandemic have seriously affected the US healthcare delivery system and the experienced Access clinical care specialists work with healthcare customers to bring a new, customized approach for remote care and quality improvement, while reducing costs related to re-admissions, utilization and overall disease management for both the patients and providers. The Australian developed and tested physician led wheezo® RAMP will be used as one of the models of care delivery for Access/Respiro in the USA.

Access and Respiro have partnered to bring a unique, patient-centric solution for management of chronic Asthma and COPD in the US and are working with some of the country’s most prestigious universities and children’s hospitals to demonstrate the value of combining the wheezo® with remote patient monitoring to help manage high-risk asthma and COPD patients.

Access has already attended the Remote Patient Monitoring Summit congress in Las Vegas, Nevada on January 31st and February 1st where they set up a conference booth display showcasing the wheezo®/Access RPM solution to numerous healthcare institutions, payors, hospitals and physician groups requesting further information and devices to begin the evaluation process required to then include the wheezo®/Access RPM solution into the services that they offer and reimburse. Further, Access and Respiro will attend the American Academy of Allergy, Asthma and Immunology (AAAAI) meeting in Phoenix, Arizona on February 25th-28th 2022. This conference is attended by physicians, other healthcare professional, pharmaceutical companies and others with a strong interest in respiratory medicine. A wheezo®/Access conference booth display will be set up to showcase the wheezo®/Access RPM solution to these key target customers.

The RPM market in the USA is forecasted to show annual growth exceeding 30% in 2026 to US\$85 billion¹. This market is highly fragmented, with no one national RPM provider. Respiro continues to execute its stated USA commercialisation strategy by pursuing and establishing numerous RPM partnerships with premier organisations like Access, which should be finalised progressively during 2022. The Company continues to ramp up efforts and activities in the next critical phase of the US commercialisation pathway which is actively engaging with the Company’s RPM partners’ customers and very good progress has been made in a relatively short period.

- ENDS -

¹ <https://www.businesswire.com/news/home/20210720005704/en/85-Bn-Remote-Patient-Monitoring-Market---Global-Forecasts-from-2021-to-2026---ResearchAndMarkets.com>

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respiri Limited
P: +61 408 462 873
E: marjan@respiri.co

Mr Nicholas Smedley
Executive Chairman
Respiri Limited
P: +61 447 074 160
E: nicholas@respiri.co

This ASX announcement dated 7 February 2022 has been authorised for release by the Board of Directors of Respiri Limited.

About Respiri Limited

Respiri is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo®, Respiri's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo® is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians and other health care professionals.

Respiri's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiri Limited's operations are based in Melbourne, Australia.

For additional information about Respiri and its products, please visit www.respiri.co

About wheezo®

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo® device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

For further information about wheezo®, follow the online link <https://wheezo.com>

wheezo® is a registered trademark of Respiri Limited.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respiri only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.